Avandia (rosiglitazone), the diabetes drug, may soon be pulled from markets around the world after a study discovered it increased the risk of heart attack by 45 per cent.  America's drug regulator, the Food and Drug Administration (FDA), has issued an urgent safety alert, and is likely to follow up with a complete ban ...